---
title: "VE800 Plus Nivolumab Phase 1 (CONSORTiUM-IO) in Select Refractory or Metastatic Cancers"
id: "medrxiv-13-consortium-io-a-phase-1-study-evaluating-ve800-plus-nivolumab-in-treatment-of"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-13-consortium-io-a-phase-1-study-evaluating-ve800-plus-nivolumab-in-treatment-of"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.11.13.26368051v1?rss=1"
published_at: "2026-11-17T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# VE800 Plus Nivolumab Phase 1 (CONSORTiUM-IO) in Select Refractory or Metastatic Cancers
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-13-consortium-io-a-phase-1-study-evaluating-ve800-plus-nivolumab-in-treatment-of
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.11.13.26368051v1?rss=1)
- **Published At:** 2026-11-17T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- CONSORTiUM-IO was an open-label, first-in-human phase 1 trial testing **VE800** combined with **nivolumab** in three cohorts: PD-1–refractory melanoma, PD-1–naive gastric/gastroesophageal junction adenocarcinoma (G/GEJ), and PD-1–naive microsatellite-stable colorectal cancer (**MSS CRC**). - The investigational product **VE800** is a defined consortium of 11 commensal bacterial strains grown from clonal cell banks, developed to avoid the variability and pathogen risk of fecal microbiota transplantation (**FMT**). - Investigators reported that the combination was generally well tolerated across cohorts; no new safety signals relative to expectations were reported in the abstract. - Efficacy outcomes did not improve on historic response rates for the included indications according to the authors; the study did not demonstrate a population-level response benefit. - Exploratory analyses in the melanoma cohort indicated that detectable **VE800** strain engraftment associated with longer progression-free survival (PFS) and with increased peripheral immune activation measures. - Preclinical data supporting the trial included increased anti–PD-1 efficacy with **VE800** in animal cancer models; the human trial sought to translate those signals. - The study was multicenter and conducted under Good Clinical Practice with IRB approvals at participating sites; the trial is registered as NCT04208958. - Genome and metagenomic sequencing data are publicly deposited (BioProject accessions reported), and other raw data are available in supplementary tables; additional materials require a material transfer agreement with Vedanta Biosciences. - Several authors are employees or advisors of Vedanta Biosciences and hold related equity or patents; the company holds patents cited in the source. - The authors noted limits: the combination did not exceed historic response benchmarks, and reported findings about engraftment and immune activation were exploratory and hypothesis-generating rather than confirmatory.
## Clinical Analysis & Structured Key Points
[](https://www.medrxiv.org/cdn-cgi/content?id=afYOx8YO1FCu1C_BNBBNl4OWHilPw2JhobCX1QV_tj0-1794954238.8203049-1.2.1.1-JXTkO7CXmEvL.JE6xYsXhY0DMSSBFvAv5ud3llOwKVU9yGsdNXAyC5gqCTXTy.E3) [Skip to main content](https://www.medrxiv.org/content/10.64898/2026.11.13.26368051v1?rss=1#main-content) [![medRxiv](https://www.medrxiv.org/sites/default/files/medrxiv_inner_logo.png)](https://www.medrxiv.org/) * [Home](https://www.medrxiv.org/) * [Submit](https://www.medrxiv.org/submit-a-manuscript) * [FAQ](https://www.medrxiv.org/about/FAQ) * [Blog](https://connect.medrxiv.org/news/) * [ALERTS / RSS](https://www.medrxiv.org/content/alertsrss) * [Resources](https://connect.medrxiv.org/resources/) * [About](https://www.medrxiv.org/content/about-medrxiv) Search for this keyword [Advanced Search](https://www.medrxiv.org/search) Follow this preprint # CONSORTiUM-IO: A Phase 1 Study Evaluating VE800 Plus Nivolumab in Treatment of Select Refractory or Metastatic Cancers [ View ORCID Profile](http://orcid.org/0000-0002-2964-1624)Carolina Lyon De Ana, Rajita Menon, Shakti K. Bhattarai, Amanda L Prince, Scott Buresh, Erica Darrah, Jason M Norman, Rose L Szabady, Dmitri Bobilev, Bruce Roberts, Judy S Wang, [ View ORCID Profile](http://orcid.org/0000-0002-3257-2922)Vanni Bucci, [ View ORCID Profile](http://orcid.org/0000-0002-2691-4500)Jeremiah J Faith, Jeffrey L Silber, Kenya Honda, Bernat Olle, Diwakar Davar doi: https://doi.org/10.64898/2026.11.13.26368051 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Carolina Lyon De Ana 1 Glaxo Smith Klein; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Carolina%2BLyon%2BDe%2BAna%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Lyon%20De%20Ana%20C&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ACarolina%2BLyon%2BDe%2BAna%2B) * [ORCID record for Carolina Lyon De Ana](http://orcid.org/0000-0002-2964-1624 "Open in new tab") Rajita Menon 2 Vedanta Biosciences, Inc., Cambridge, MA, USA; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Rajita%2BMenon%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Menon%20R&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ARajita%2BMenon%2B) Shakti K. Bhattarai 3 Program in Microbiome Dynamics, Department of Microbiology, University of Massachusetts Chan Medical School, Worcester, MA; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Shakti%2BK.%2BBhattarai%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Bhattarai%20SK&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AShakti%2BK.%2BBhattarai%2B) Amanda L Prince 4 CSL Behring, Waltham, MA; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Amanda%2BL%2BPrince%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Prince%20AL&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AAmanda%2BL%2BPrince%2B) Scott Buresh 5 Tokyo Chemical Industry, Portland, OR; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Scott%2BBuresh%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Buresh%20S&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AScott%2BBuresh%2B) Erica Darrah 6 Veeva Systems, Boston, MA; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Erica%2BDarrah%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Darrah%20E&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AErica%2BDarrah%2B) Jason M Norman 2 Vedanta Biosciences, Inc., Cambridge, MA, USA; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Jason%2BM%2BNorman%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Norman%20JM&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AJason%2BM%2BNorman%2B) Rose L Szabady 7 Ferring Pharmaceuticals, Parsippany, NJ; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Rose%2BL%2BSzabady%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Szabady%20RL&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ARose%2BL%2BSzabady%2B) Dmitri Bobilev 2 Vedanta Biosciences, Inc., Cambridge, MA, USA; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Dmitri%2BBobilev%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Bobilev%20D&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ADmitri%2BBobilev%2B) Bruce Roberts 2 Vedanta Biosciences, Inc., Cambridge, MA, USA; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Bruce%2BRoberts%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Roberts%20B&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ABruce%2BRoberts%2B) Judy S Wang 8 Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, FL; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Judy%2BS%2BWang%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Wang%20JS&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AJudy%2BS%2BWang%2B) Vanni Bucci 9 UMass Medical School; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Vanni%2BBucci%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Bucci%20V&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AVanni%2BBucci%2B) * [ORCID record for Vanni Bucci](http://orcid.org/0000-0002-3257-2922 "Open in new tab") Jeremiah J Faith 10 Icahn School of Medicine at Mount Sinai; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Jeremiah%2BJ%2BFaith%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Faith%20JJ&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AJeremiah%2BJ%2BFaith%2B) * [ORCID record for Jeremiah J Faith](http://orcid.org/0000-0002-2691-4500 "Open in new tab") * For correspondence: jeremiah.faith@mssm.edu Jeffrey L Silber 2 Vedanta Biosciences, Inc., Cambridge, MA, USA; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Jeffrey%2BL%2BSilber%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Silber%20JL&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AJeffrey%2BL%2BSilber%2B) Kenya Honda 11 RIKEN Center for Integrative Medical Sciences, Yokohama, Japan; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Kenya%2BHonda%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Honda%20K&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AKenya%2BHonda%2B) Bernat Olle 2 Vedanta Biosciences, Inc., Cambridge, MA, USA; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Bernat%2BOlle%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Olle%20B&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ABernat%2BOlle%2B) Diwakar Davar 12 UPMC Hillman Cancer Center, Pittsburgh, PA * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Diwakar%2BDavar%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Davar%20D&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ADiwakar%2BDavar%2B) * [Abstract](https://www.medrxiv.org/content/10.64898/2026.11.13.26368051v1)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_art/node:1347370/1) * [Info/History](https://www.medrxiv.org/content/10.64898/2026.11.13.26368051v1.article-info)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_info/node:1347370/1) * [Metrics](https://www.medrxiv.org/content/10.64898/2026.11.13.26368051v1.article-metrics)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_metrics/node:1347370/1) * [Supplementary material](https://www.medrxiv.org/content/10.64898/2026.11.13.26368051v1.supplementary-material)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_data/node:1347370/1) * [Data/Code](https://www.medrxiv.org/content/10.64898/2026.11.13.26368051v1.external-links)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_data_code/node:1347370/1) * [ Preview PDF](https://www.medrxiv.org/content/10.64898/2026.11.13.26368051v1.full.pdf+html)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_pdf/node:1347370/1) ![Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif) ## Abstract Microbiome modulation can augment responses to immunotherapy in advanced cancer. Early studies of anti-PD-1 therapies in combination with fecal microbiota transplantation (FMT) reported efficacy in immunotherapy-naive and -refractory settings. However, FMTs are variable in composition, difficult to scale, and risk the transfer of emerging pathogens. VE800 is a consortium of 11 strains of commensal bacteria derived from healthy donors and grown from clonal cell banks. VE800 increased anti-PD-1 efficacy in preclinical models of cancer. CONSORTiUM-IO was a first-in-human, open-label phase 1 study that evaluated safety and efficacy of VE800 with nivolumab in advanced PD-1-refractory melanoma, PD-1-naive gastric/gastroesophageal junction (G/GEJ) adenocarcinoma and PD-1-naive microsatellite-stable colorectal cancer (MSS CRC). VE800 plus nivolumab was well tolerated but offered no improvement over historic response rates. Exploratory analyses in patients with melanoma revealed that VE800 strain engraftment was associated with greater progression-free survival (PFS) and increased immune activation peripherally. ### Competing Interest Statement R.M, J.M.N., J.L.S. and B.O. are employees of Vedanta Biosciences and have an equity interest in the company. Vedanta Biosciences holds patents related to this work. C.L.D.A., A.P., S.B., E.D., R.S., D.B. and B.R., were employees of Vedanta Biosciences and had an equity interest in the company at the time of their contribution. V.B. and J.F. are members of the scientific advisory board of Vedanta Biosciences and an equity interest in the company. S.K.B. has no competing interest. J.W. is affiliated to the American Society of Clinical Oncology. D.D. is affiliated to data and safety monitoring board (DSMB), study steering committee membership (Immunocore, Immatics, Replimmune); scientific advisory board membership (Xilio Therapeutics); consultancy with compensation (ACM Bio, Ascendis, Castle, Clinical Care Options, Gerson Lehrman Group, Immunitas, Medical Learning Group, Regeneron, Replimmune, Trisalus, Xilio Therapeutics); grants/research support (Arcus, Immunocore, Merck, Regeneron Pharmaceuticals Inc., Tesaro/GSK); CE speakers bureau (Castle Biosciences, Regeneron); stockholder (Arcamyra, mBiomics, Pienomial, Zola). Intellectual Property: US Patent 63/124,231, Compositions and Methods for Treating Cancer, Dec 11, 2020 US Patent 63/208,719, Compositions and Methods For Responsiveness to Immune Checkpoint Inhibitors (ICI), Increasing Effectiveness of ICI and Treating Cancer, June 9, 2021. The authors vouch for the accuracy and completeness of the data and data analyses. ### Clinical Trial NCT04208958 ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: This multi-center study was conducted in accordance with Good Clinical Practice guidelines. The protocol and informed consent documents were approved by the Institutional Review Board or ethics committee for each participating site, and all patients provided written informed consent before any study procedure. Approving boards and protocol numbers were: University of Utah IRB (IRB_00128490); University of Pittsburgh Medical Center IRB (MOD00655221, Pro00039903); Advarra Center for IRB Intelligence Platform (MOD00655221, MOD0146106, 00000971); WCG Institutional Review Board (study numbers 1282434, 1273387, 1275793, 1283587); New York University School of Medicine (i19-00845); Rhode Island Hospital & Miriam Hospital (204120); University of California Los Angeles (IRB#20000133-AM00006); Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute (CR2019-1002-0); University of Chicago Medical Center (IRB19-1676); Sutter Health IRB (1549521-7); and Weill Cornell Medicine (20-02021418). I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes ## Data Availability VE800 strain genomes are available under BioProject PRJEB29940. Metagenomic sequencing data are available under BioProject PRJNA1460837. VE800 strain assignments were assessed using the Genome Taxonomy Database Version 207. All other raw data for analyses are available in supplementary tables. Other materials generated in the study will be made available under a material transfer agreement with Vedanta Biosciences. Correspondence should be addressed to legal{at}vedantabio.com and the corresponding authors. Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. bioRxiv and medRxiv thank the following for their generous financial support: > The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam. [Donate to openRxiv ](https://www.zeffy.com/en-US/donation-form/donate-to-make-a-difference-10981) [ Back to top](https://www.medrxiv.org/content/10.64898/2026.11.13.26368051v1?rss=1#page) [ Previous](https://www.medrxiv.org/content/10.64898/2026.11.16.26367991v1 "ZNF683-positive tissue-resident memory T cells organize treatment-refractory niches with targetable circuits in inclusion body myositis")[Next ](https://www.medrxiv.org/content/10.64898/2026.11.14.26368080v1 "Normative Modeling of Structural and Diffusion MRI for Epilepsy Diagnosis and Classification") Posted November 17, 2026. [ Download PDF](https://www.medrxiv.org/content/10.64898/2026.11.13.26368051v1.full.pdf) Print/Save Options [Download PDF](https://www.medrxiv.org/content/medrxiv/early/2026/11/17/2026.11.13.26368051.full.pdf)Full Text & In-line FiguresXML [More Info](https://www.medrxiv.org/about/FAQ#PrintOptions "More Information on Print/Save Options") [ Author Declarations](https://www.medrxiv.org/content/10.64898/2026.11.13.26368051v1#p-5) [Supplementary Material ](https://www.medrxiv.org/content/10.64898/2026.11.13.26368051v1.supplementary-material) [ Data/Code](https://www.medrxiv.org/content/early/2026/11/17/2026.11.13.26368051.external-links) [ Email](https://www.medrxiv.org/ "Email this Article") [ Share](https://www.medrxiv.org/) CONSORTiUM-IO: A Phase 1 Study Evaluating VE800 Plus Nivolumab in Treatment of Select Refractory or Metastatic Cancers Carolina Lyon De Ana, Rajita Menon, Shakti K. Bhattarai, Amanda L Prince, Scott Buresh, Erica Darrah, Jason M Norman, Rose L Szabady, Dmitri Bobilev, Bruce Roberts, Judy S Wang, Vanni Bucci, Jeremiah J Faith, Jeffrey L Silber, Kenya Honda, Bernat Olle, Diwakar Davar medRxiv 2026.11.13.26368051; doi: https://doi.org/10.64898/2026.11.13.26368051 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Share This Article: Copy [![Twitter logo](https://www.medrxiv.org/sites/all/m
## Related Clinical Research

- [Predicting Cancer Immunotherapy Response Using Dynamic CD8+ T Cell Changes — Pan‑Cancer Retrospect](https://medichelpline.com/clinical-feed/frontiers-in-immunology-13-a-predictive-model-for-immunotherapy-efficacy-in-cancer-based-on-dynamic.md)
- [Ipilimumab plus Nivolumab Yields 50% Observed ORR in Small WD‑NET Phase II Cohort](https://medichelpline.com/clinical-feed/frontiers-in-immunology-4-dual-immune-checkpoint-blockade-in-advanced-well-differentiated-neuroendocrine.md)
- [Amsokigene autoleucel TIL Therapy Shows Promise in ICI-Resistant Advanced Melanoma Trials](https://medichelpline.com/clinical-feed/nature-1-regulatable-membrane-bound-il-15-engineered-til-cell-therapy-for-immune.md)
- [Dual immune checkpoint inhibition for melanoma brain metastases: safety and efficacy meta-analysis](https://medichelpline.com/clinical-feed/pubmed-42934318.md) (DOI: 10.1007/s10143-026-04538-w)
- [Relatlimab plus nivolumab 5-year outcomes in advanced melanoma: RELATIVITY-047 survival and biomar](https://medichelpline.com/clinical-feed/nature-0-relatlimab-plus-nivolumab-versus-nivolumab-for-advanced-melanoma-5-year.md)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.